GSK plc, the renowned British pharmaceutical company, has announced its agreement to acquire IDRx, a Boston-based biopharmaceutical entity in its clinical-stage, for a total consideration of up to $1.15 billion in cash. This strategic acquisition will include IDRX-42, a cutting-edge KIT Tyrosine Kinase Inhibitor, currently being developed for both first- and second-line treatments for gastrointestinal stromal tumors (GIST).
The acquisition deal comprises an upfront payment of $1 billion, with an additional potential $150 million contingent upon regulatory approval successes. Furthermore, GSK will undertake responsibility for milestone payments linked to success and will pay tiered royalties related to IDRX-42 to its development partner, German pharmaceutical company Merck KGaA.
GIST typically manifests within the gastrointestinal tract, with 80 percent of cases attributed to mutations in the KIT gene. These mutations are known to enhance tumor cell growth and survival. Post initial treatment, a significant 90 percent of patients experience additional KIT mutations, leading to relapses and limited therapeutic options. As of now, no approved Tyrosine Kinase Inhibitors (TKIs) target all clinically significant primary and secondary KIT mutations.
GSK has highlighted that IDRX-42 is effective against all main KIT mutations, offering the potential to significantly improve treatment outcomes for GIST patients. Tony Wood, GSK's Chief Scientific Officer, expressed enthusiasm regarding the promising early data from IDRX-42 and its unparalleled ability to address all clinically significant KIT mutations present in GIST — a substantial shortcoming in the current standard of care. He further noted GSK’s intent to expedite the drug’s development in 2025 to revolutionize treatment protocols.
On the trading front, GSK's stock has seen a slight dip, trading 0.82% lower at 1,338.50 pence on the London Stock Exchange.
The material has been provided by InstaForex Company -
www.instaforex.com
